Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03083353 · ClinicalTrials.gov registry record · Early Phase 1
Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation
A Early Phase 1 study, sponsored by Jasper A. Smits.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 78
- Enrollment target
NCT03083353 is a Early Phase 1 study that has completed, run by Jasper A. Smits. The registered enrollment target is 78 participants.
The verdict
NCT03083353, a Early Phase 1 study, has completed, sponsored by Jasper A. Smits.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.
Interventions
- DRUG Isradipine
- BEHAVIORAL Cue Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2023-06-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03083353
The ClinicalTrials.gov registry entry for NCT03083353 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jasper A. Smits, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isradipine is the first listed.
NCT03083353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03083353 about?
NCT03083353 is a clinical study titled "Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation". The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and effic...
What is the current status of trial NCT03083353?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 78 participants. The study started on 2020-01-22. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT03083353?
The interventions under investigation include: Isradipine (DRUG), Cue Exposure (BEHAVIORAL).
Who is sponsoring clinical trial NCT03083353?
This trial is sponsored by Jasper A. Smits, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.